Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods: The study population comprised patients with AGC in the AGAMENON r...

ver descrição completa

Detalhes bibliográficos
Autores: Cotes Sanchís, Almudena, Gallego, Javier, Hernandez, Raquel, Arrazubi, Virginia, Custodio, Ana, Cano, Juana María, Aguado, Gemma, Macias, Ismael, Lopez, Carlos, López, Flora, Visa, Laura, Garrido, Marcelo, Martínez Lago, Nieves, Fernández Montes, Ana, Limón, María Luisa, Azkarate, Aitor, Pimentel, Paola, Reguera, Pablo, Ramchandani, Avinash, Cacho, Juan Diego, Martín Carnicero, Alfonso, Granja, Mónica, Martín Richard, Marta, Hernández Pérez, Carolina, Hurtado, Alicia, Serra, Òlbia, Buxo, Elvira, Vidal Tocino, Rosario, Jiménez Fonseca, Paula, Carmona Bayonas, Alberto
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/173470
Acesso em linha:https://hdl.handle.net/2445/173470
Access Level:acceso abierto
Palavra-chave:Càncer d'estómac
Qualitat de vida
Metàstasi
Stomach cancer
Quality of life
Metastasis
Descrição
Resumo:Background: Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. Materials and methods: The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). Results: 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's tau = 0.613), lower in those subjects who received second-line (Kendall's tau = 0.539), especially with ramucirumab+CT (Kendall's tau = 0.413). Conclusion: This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines.

Registos relacionados